Why Is Vigil Neuroscience (VIGL) Stock Up 32% Today?

Vigil Neuroscience (NASDAQ:VIGL) stock is soaring higher on Thursday after the clinical-stage biotechnology company revealed a $40 million strategic investment from Sanofi (NASDAQ:SNY). As part of this investment agreement, Vigil Neuroscience is granting Sanofi exclusive right of first negotiation (ROFN) for its molecule TREM2 agonist program. This covers the exclusive license, grant or transfer of rights to research, development, manufacturing and commercialization. Vigil Neuroscience president and CEO Iva ...